Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(3):345-359. Published online March 12, 2024

DOI: https://doi.org/10.3350/cmh.2023.0553

View: 3474 Download: 363 Web of Science: 1 Crossref: 3

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(3):763-778. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0076

View: 3569 Download: 208 Web of Science: 4 Crossref: 6

Editorial

The prime time for management of hepatocellular carcinoma in Hong Kong

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(2):345-348. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0094

View: 2843 Download: 59

Letter to the Editor

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma

Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura

Clin Mol Hepatol. 2021;27(4):616-619. Published online September 13, 2021

DOI: https://doi.org/10.3350/cmh.2021.0258

View: 5291 Download: 206 Web of Science: 4 Crossref: 4

1 |

Viewed By 5157	MAFLD: How is it different from NAFLD?
Viewed By 4902	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4875	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4592	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4570	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search